Lymphoid Malignancies clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 12-95
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.
Los Angeles, California and other locations
Our lead scientists for Lymphoid Malignancies research studies include Gary Schiller.